Study of features of drug metabolism in patients with chronic liver diseases
Abstract
In one-stage opened research activity of isoenzymes СYР3А4 and CYP2C9 of system of biotransformation of medicines at patients with chronic diffusive liver diseases — residents of Volgograd and the Volgograd region is defined. It is established that the greatest decrease in activity of isoenzyme СYР3А4 is connected with chronic virus hepatitis C (for 57 % from normal values), in other groups as decrease in activity of an isoenzyme is noted: at primary biliary cirrhosis (for 43,5 %), alcoholic liver disease (for 39 %) and nonalcoholic fatty liver disease (fatty liver) (for 33 %). At all patients with chronic diffusive liver diseases as decrease in activity of an isoenzyme of CYP2C9 is noted. In group of chronic virus hepatitis C (for 48 % from normal values), primary biliary cirrhosis (for 41,2 %), nonalcoholic fatty liver disease (fatty liver) (for 23,4 %), alcoholic liver disease (for 20,5 %).
About the Authors
N. V. Rogova
Medical University “Volgograd State Medical University” of Ministry of Health of Russia, Volgograd
Russian Federation
Department of Clinical Pharmacology and Intensive Care
Russian Federation
Department of Clinical Pharmacology and Intensive Care
V. I. Statcenko
Medical University “Volgograd State Medical University” of Ministry of Health of Russia, Volgograd
Russian Federation
Department of Clinical Pharmacology and Intensive Care
Russian Federation
Department of Clinical Pharmacology and Intensive Care
References
1. Белоусов Ю.Б., Кукес В.Г., Лепахин В.К., Петров В.И. Клиническая фармакология: национальное руководство. — М.: ГОЭТАР-Медиа, 2009. — с. 854 — 868.
2. Ивашкин В.Т. Оценка функционального состояния печени // Болезни печени и желчевыводящих путей / 2-е изд., испр. и доп. — М.:Изд. дом «М-Ве-сти», 2005. — С. 66-84.
3. Калинина А.В., Хазанова А.И. Гастроэнтерология и гепатология: диагностика и лечение. Руководство для врачей — М.: Изд. Миклош, 2007. — 600 с.
4. Петров В.И., Рогова Н.В., Ледяев Я.М., Сердюкова Д.М. Изучение влияния длительной терапии производными сульфонилмочевины на емкость ферментной системы биотрансформации лекарственных средств в печени (изофермента CYP2C9) у больных сахарным диабетом типа 2 в Волгограде. Вестник ВолгГМУ. — 2010. — №2(34). — С. 14 — 18.
5. American gastroenterological association Technical Review on Nonalcoholic Fatty Liver Disease. Gastroenterology 2002; Vol. 123, No. 5:1705—1725.
6. Craig D. et al. Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease. Drug Metab Dispos. 2009 October; 37(10): 2087—2094.
7. Day C.P. Nonalcoholic fatty liver disease: current concepts and management strategies. Clin Med 6:19—25, 2006.
8. Jae S. Lee, R. Scott Obach, Michael B. Fisher. Drug Metabolising enzymes. Cytochrome P450 and other enzymes in drug discovery and development. 2003. 155, 173, 190.
9. Ryota Kikuchi., et al. Eff ect of Hepatitis C Virus Infection on the mRNA Expression of Drug Transporters and Cytochrome P450 Enzymes in Chimeric Mice with Humanized Liver. DMD November 2010 vol. 38 no. 11 1954-1961.
10. World Health Organization. Global status report on alcohol 2004. Geneva. 2004. — P. 1— 94.
Review
For citations:
Rogova N.V., Statcenko V.I. Study of features of drug metabolism in patients with chronic liver diseases. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2014;(2):66-69. (In Russ.)
Views:
500
Email this article 